PPI Sequencing study
Study identifier:D9612L00104
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A study to Assess the effectiveness of Esomeprazole 40 mg once daily in subjects with continuing Gastroesophageal Reflux Disease (GORD) symptoms following treatment wit a previous full dose Proton Pump Inhibitor (PPI)
Medical condition
Gastro-oesophageal reflux disease
Phase
Phase 4
Healthy volunteers
No
Study drug
Esomeprazole
Sex
All
Actual Enrollment
100
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Sept 2006
Primary Completion Date: 01 May 2007
Study Completion Date: 01 May 2007
Study design
Allocation: Non-randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
Rhiannon Rowsell
AstraZeneca
